Journal Club Summary
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M.
PLATO was a multicentre, randomized, double-dummy, double blind trial conducted to determine if ticagrelor is superior to clopidogrel for the prevention of vascular events and death in patients with ACS and the study demonstrated a significant reduction of the composite primary endpoint of cardiovascular death, MI and stroke in the ticagrelor group. This is a practice-changing study with ticagrelor recently replacing clopidogrel in our code STEMI protocol but as a group we identified that the drug is significantly underutilized in cases of NSTEMI and UA, perhaps due to cost.
(Presented February 2013)